Halozyme Therapeutics (GB:0J2O)
UK Market

Halozyme Stock Analysis & Ratings

GB:0J2O Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.00 - $0.00
Previous Close$41.27
Average Volume (3M)203.00
Market Cap$5.69B
P/E RatioN/A
Next EarningsAug 09, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score10
EPS (TTM)0.00



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.



What was Halozyme’s price range in the past 12 months?
Halozyme lowest stock price was $0.00 and its highest was $0.00 in the past 12 months.
    What is Halozyme’s market cap?
    Halozyme’s market cap is $5.69B.
      What is Halozyme’s price target?
      The average price target for Halozyme is $53.00. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $58.00 ,the lowest forecast is $45.00. The average price target represents 28.41% Increase from the current price of $41.273.
        What do analysts say about Halozyme?
        Halozyme’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
          When is Halozyme’s upcoming earnings report date?
          Halozyme’s upcoming earnings report date is Aug 09, 2022 which is in 78 days.
            How were Halozyme’s earnings last quarter?
            Halozyme released its earnings results on May 10, 2022. The company reported $0.43 earnings per share for the quarter, missing the consensus estimate of $0.461 by -$0.031.
              Is Halozyme overvalued?
              According to Wall Street analysts Halozyme’s price is currently Undervalued.
                Does Halozyme pay dividends?
                Halozyme does not currently pay dividends.
                What is Halozyme’s EPS estimate?
                Halozyme’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Halozyme have?
                Halozyme has 137,950,000 shares outstanding.
                  What happened to Halozyme’s price movement after its last earnings report?
                  Halozyme reported an EPS of $0.43 in its last earnings report, missing expectations of $0.461. Following the earnings report the stock price went same 0%.
                    Which hedge fund is a major shareholder of Halozyme?
                    Among the largest hedge funds holding Halozyme’s share is Fisher Asset Management LLC. It holds Halozyme’s shares valued at 38M.


                      Halozyme Stock Analysis

                      Smart Score
                      Price Target
                      ▲(28.41% Upside)
                      Strong Buy
                      The Halozyme stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Halozyme Therapeutics

                      Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development & commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

                      Similar Stocks
                      Price & Change
                      Johnson & Johnson
                      Eli Lilly & Co
                      Roche Holding

                      Popular Stocks

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis